COVID-19
My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.

Emily Littlejohn ELittlejohnDO
3 years 6 months ago
Love this COVID ARDS risk calculator put forth by @JYazdanyMD at #ACR21 for our patient's with Rheumatic Diseases. A wonderful resource in talking to our patients about vaccine necessity! @CleClinicMD https://t.co/EA5jVYweHm


Marie Kuchynski MD Doctorkuch
3 years 6 months ago
#ACR21 Late breaking
#ACRambassador
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled EMR Data Repository https://t.co/oyovR27Upm

swethaann23 swethaann23
3 years 6 months ago
Reasons for COVID-19 vaccine hesitancy in rheumatology pts in southeast US based on survey study:
🔰Vaccine being “rushed” or “experimental”
🔰Safety of vaccine in the patients’ rheumatologic diagnoses
🔰Side effects
🔰Concern for Allergic reaction
Abst#1589 #ACR21 @RheumNow https://t.co/xm15KxdA56


Dr. John Cush RheumNow
3 years 6 months ago
Factors Associated with Poor Vaccine Response in Rituximab: Dr. Yuzaiful Yusof (@Yuz6Yusof) discusses abstract #0437 presented at the #ACR21 annual meeting.
https://t.co/T0PFiZlbTa https://t.co/idj5T7j7ke


Dr. John Cush RheumNow
3 years 6 months ago
Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE from Dr. Yuz Yusof ( @Yuz6Yusof)
It's almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under EUA. But is the vaccine safe for people with lupus?
https://t.co/i3HeCvS6El https://t.co/Tn0nWKrK4T

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.

Richard Conway RichardPAConway
3 years 6 months ago
GRA @rheum_covid data presented by @mugartegil. African-American and Hispanic individuals with SLE have MUCH worse COVID-19 outcomes. Likely related socioeconomic and health disparities. Abstr#1933 #ACR21 @RheumNow https://t.co/YUoOeIxN7O


Aurelie Najm AurelieRheumo
3 years 6 months ago
🚫Infection risk after COVID vaccination: US database
536 954 Controls and 47 303 pts w/ RMDs
〽️BNT162b2 19 vs. 36/1000
〽️ mRNA-1273 16 vs. 33/1000 〽️Janssen 26 vs. 47/1000
Infections ⬆️ RA, SpA, SLE, SSc, Polymyositis
#ACR21 #AbstL16 @RheumNow
https://t.co/xzOaFIu06e
@RheumNow https://t.co/tmr4USETJ3


Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#ACR21 #AbstrL17 In pts treated with Rituximab, arrange a 3rd primary dose ASAP regardless mRNA or vector #COVID vaccine. An RCT of N=60 pts who did not seroconvert after primary dose, overall 94% either seroconverted/new T-cell response @RheumNow #ACRBest https://t.co/F15j93OFE4 https://t.co/tXoisoYthx


Akhil Sood MD AkhilSoodMD
3 years 6 months ago
CH COVID 19 Poster Review
Abst 0196
Jackson & colleagues performed double blind RCT of anakinra in patients with features of COVID-19 cytokine storm
- Anakinra + GC did not significantly impact outcomes in patients with cytokine storm syndrome
#ACR21 @RheumNow https://t.co/hX7bBtrIzT


Dr. Rachel Tate uptoTate
3 years 6 months ago
Late breaking, but just in time! mRNA COVID-19 3rd dose in RTX pts, w/o Ab response post initial series. After 3rd dose many had ab response or T cell response.
Extra vaccine full doses can protect RTX pts from COVID! AbsL17 #ACRbest #ACR21 @RheumNow https://t.co/lIDPzybmT7 https://t.co/jEJ3N6cdjK


Dr. John Cush RheumNow
3 years 6 months ago
Complications of Covid19 in Lupus: Dr. Kathryn Dao ( @KDAO2011) discusses abstract #1933 presented at the #ACR21 annual meeting.
https://t.co/jKFJwCBeCo https://t.co/ncleyYZWLn
